User:Hammer q/Sofinicline
Appearance
This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Clinical data | |
---|---|
Other names | ABT-894, sofinicline besylate |
Routes of administration | Oral |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
PubChem SID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C10H11Cl2N3 |
Molar mass | 244.12 g·mol−1 |
3D model (JSmol) | |
Density | 1.406 ± 0.06 g/cm3 |
Boiling point | 417.350 ± 45.00 °C (783.230 ± 81.000 °F) Predicted |
Solubility in water | 2 g/L |
| |
|
Sofinicline is an investigational non-stimulant drug for the treatment of ADHD. It is a nicotinic acetylcholine receptor (nAChR) α4β2 agonist.[1]
References
[edit]- ^ Fleisher C, McGough J (August 2014). "Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder". Expert Opinion on Investigational Drugs. 23 (8): 1157–1163. doi:10.1517/13543784.2014.934806. PMID 24965900.